Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above 200 Day Moving Average of $0.00

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.71. Xtant Medical shares last traded at $0.68, with a volume of 5,852 shares trading hands.

Xtant Medical Stock Up 0.8 %

The company has a debt-to-equity ratio of 0.49, a current ratio of 2.44 and a quick ratio of 1.01. The firm has a market cap of $88.68 million, a P/E ratio of -68.05 and a beta of 0.36.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings data on Thursday, August 8th. The medical device company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Xtant Medical had a negative net margin of 3.00% and a negative return on equity of 6.71%. The firm had revenue of $29.94 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xtant Medical stock. Vanguard Group Inc. grew its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 3.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,548,312 shares of the medical device company’s stock after purchasing an additional 48,319 shares during the quarter. Vanguard Group Inc. owned 1.19% of Xtant Medical worth $1,812,000 at the end of the most recent quarter. 69.33% of the stock is owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.